-
Je něco špatně v tomto záznamu ?
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
M. Cuchel, FJ. Raal, RA. Hegele, K. Al-Rasadi, M. Arca, M. Averna, E. Bruckert, T. Freiberger, D. Gaudet, M. Harada-Shiba, LC. Hudgins, M. Kayikcioglu, L. Masana, KG. Parhofer, JE. Roeters van Lennep, RD. Santos, ESG. Stroes, GF. Watts, A....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
- MeSH
- anticholesteremika * terapeutické užití MeSH
- ateroskleróza * farmakoterapie MeSH
- homozygot MeSH
- homozygotní familiární hypercholesterolemie * MeSH
- hyperlipoproteinemie typ II * diagnóza genetika terapie MeSH
- LDL-cholesterol genetika MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy-both pharmacologic intervention and lipoprotein apheresis (LA)-is foundational. Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA. To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost. This updated statement provides guidance that is crucial to early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.
Academic Research Organization Hospital Israelita Albert Einstein Sao Paulo Brazil
Cardiovascular Center Osaka Medical and Pharmaceutical University Osaka Japan
Department of Cardiology Faculty of Medicine Ege University Izmir Turkey
Department of Cardiology Hacettepe University Faculty of Medicine Ankara Turkey
Department of Internal Medicine Erasmus MC Medical Center Rotterdam The Netherlands
Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
European Atherosclerosis Society Gothenburg Sweden
Istituto di Biofisica Consiglio Nazionale delle Ricerche Genova Italy
Lipid Clinic Heart Institute University of São Paulo Medical School Hospital São Paulo Brazil
Medizinische Klinik und Poliklinik 4 Ludwigs Maximilians University Klinikum Munich Germany
Pitié Salpêtrière Hospital and Sorbonne University Cardio metabolic Institute Paris France
Rogosin Institute Weill Cornell Medical College New York NY USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23017005
- 003
- CZ-PrNML
- 005
- 20231026105352.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/eurheartj/ehad197 $2 doi
- 035 __
- $a (PubMed)37130090
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cuchel, Marina $u Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 9017 Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA $1 https://orcid.org/0000000168083824
- 245 10
- $a 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance / $c M. Cuchel, FJ. Raal, RA. Hegele, K. Al-Rasadi, M. Arca, M. Averna, E. Bruckert, T. Freiberger, D. Gaudet, M. Harada-Shiba, LC. Hudgins, M. Kayikcioglu, L. Masana, KG. Parhofer, JE. Roeters van Lennep, RD. Santos, ESG. Stroes, GF. Watts, A. Wiegman, JK. Stock, LS. Tokgözoğlu, AL. Catapano, KK. Ray
- 520 9_
- $a This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy-both pharmacologic intervention and lipoprotein apheresis (LA)-is foundational. Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin/kexin type 9, followed by evinacumab and/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA. To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost. This updated statement provides guidance that is crucial to early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a LDL-cholesterol $x genetika $7 D008078
- 650 12
- $a homozygotní familiární hypercholesterolemie $7 D000090542
- 650 12
- $a hyperlipoproteinemie typ II $x diagnóza $x genetika $x terapie $7 D006938
- 650 12
- $a anticholesteremika $x terapeutické užití $7 D000924
- 650 12
- $a ateroskleróza $x farmakoterapie $7 D050197
- 650 _2
- $a homozygot $7 D006720
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Raal, Frederick J $u Carbohydrate and Lipid Metabolism Research Unit, Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand Parktown, Johannesburg, South Africa $1 https://orcid.org/0000000291707938
- 700 1_
- $a Hegele, Robert A $u Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada $1 https://orcid.org/0000000328615325
- 700 1_
- $a Al-Rasadi, Khalid $u Department of Biochemistry, College of Medicine & Health Sciences, Medical Research Center, Sultan Qaboos University, Muscat, Oman $1 https://orcid.org/0000000304601236
- 700 1_
- $a Arca, Marcello $u Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy $1 https://orcid.org/0000000337860883
- 700 1_
- $a Averna, Maurizio $u Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities, University of Palermo, Palermo, Italy $u Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Genova, Italy $1 https://orcid.org/0000000335589209
- 700 1_
- $a Bruckert, Eric $u Pitié-Salpêtrière Hospital and Sorbonne University, Cardio metabolic Institute, Paris, France
- 700 1_
- $a Freiberger, Tomas $u Centre for Cardiovascular Surgery and Transplantation, and Medical Faculty, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000165327053 $7 xx0071641
- 700 1_
- $a Gaudet, Daniel $u Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Université de Montréal, ECOGENE, Clinical and Translational Research Center, and Lipid Clinic, Chicoutimi Hospital, Chicoutimi, Québec, Canada $1 https://orcid.org/0000000251853666
- 700 1_
- $a Harada-Shiba, Mariko $u Cardiovascular Center, Osaka Medical and Pharmaceutical University, Osaka, Japan $1 https://orcid.org/0000000276002059
- 700 1_
- $a Hudgins, Lisa C $u Rogosin Institute, Weill Cornell Medical College, New York, NY, USA
- 700 1_
- $a Kayikcioglu, Meral $u Department of Cardiology, Faculty of Medicine, Ege University, Izmir, Turkey $1 https://orcid.org/0000000336925227
- 700 1_
- $a Masana, Luis $u Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV CIBERDEM, Reus, Spain $1 https://orcid.org/0000000207894954
- 700 1_
- $a Parhofer, Klaus G $u Medizinische Klinik und Poliklinik IV, Ludwigs-Maximilians University Klinikum, Munich, Germany $1 https://orcid.org/0000000198730412
- 700 1_
- $a Roeters van Lennep, Jeanine E $u Department of Internal Medicine, Erasmus MC, Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/0000000168709962
- 700 1_
- $a Santos, Raul D $u Lipid Clinic, Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, Brazil $u Academic Research Organization Hospital Israelita Albert Einstein, Sao Paulo, Brazil $1 https://orcid.org/0000000298606582
- 700 1_
- $a Stroes, Erik S G $u Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands $1 https://orcid.org/0000000195556260
- 700 1_
- $a Watts, Gerald F $u Medical School, University of Western Australia, and Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, Perth, Australia
- 700 1_
- $a Wiegman, Albert $u Department of Pediatrics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands $1 https://orcid.org/0000000162235671
- 700 1_
- $a Stock, Jane K $u European Atherosclerosis Society, Gothenburg, Sweden
- 700 1_
- $a Tokgözoğlu, Lale S $u Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey
- 700 1_
- $a Catapano, Alberico L $u IRCCS MultiMedica, and Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy $1 https://orcid.org/0000000275932094
- 700 1_
- $a Ray, Kausik K $u Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK $1 https://orcid.org/0000000305080954
- 773 0_
- $w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 44, č. 25 (2023), s. 2277-2291
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37130090 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105347 $b ABA008
- 999 __
- $a ok $b bmc $g 2000494 $s 1203367
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 44 $c 25 $d 2277-2291 $e 2023Jul01 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
- LZP __
- $a Pubmed-20231013
